Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

@article{Veeraraghavalu2013CommentO,
  title={Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".},
  author={Karthikeyan Veeraraghavalu and Can Zhang and Sean Miller and Jasmin K Hefendehl and Tharinda W Rajapaksha and Jason Daniel Ulrich and Mathias Jucker and David M Holtzman and Rudolph E. Tanzi and Robert Vassar and Sangram S. Sisodia},
  journal={Science},
  year={2013},
  volume={340 6135},
  pages={924-f}
}
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) reported that bexarotene rapidly reduces β-amyloid (Aβ) levels and plaque burden in two mouse models of Aβ deposition in Alzheimer's disease (AD). We now report that, although bexarotene reduces soluble Aβ40 levels in one of the mouse models, the drug has no impact on plaque burden in three strains that exhibit Aβ amyloidosis. 

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 12 references

( NO TITLE )

  • S Sisodia
  • 2013

Science

  • Y S Eisele
  • Science
  • 2010

EMBO Rep

  • R Radde
  • EMBO Rep
  • 2006

J. Neurosci

  • H Oakley
  • J. Neurosci
  • 2006

Neurobiol. Dis

  • J Wang, H Tanila, J Puoliväli, I Kadish, T Van Groen
  • Neurobiol. Dis
  • 2003

Psychol. Methods

  • S B Morris, R P Deshon
  • Psychol. Methods
  • 2002

J. Biol. Chem

  • S H Kim
  • J. Biol. Chem
  • 2001

Science Biomol. Eng

  • P E Cramer
  • Science Biomol. Eng
  • 2001

Annu. Rev. Neurosci

  • D L Price, S S Sisodia
  • Annu. Rev. Neurosci
  • 1998

Acknowledgments: This work was supported by the Cure Alzheimer's Fund The authors (6135), 924. [doi: 10.1126/science

  • Acknowledgments: This work was supported by the…
  • 1235

Similar Papers

Loading similar papers…